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The synthesis and the effect of a combination of 6-glycine and 14-phenylpropoxy substitutions in N-
methyl- and N-cycloproplymethylmorphinans on biological activities are described. Binding studies
revealedthatallnew14-phenylpropoxymorphinans(11-18)displayedhighaffinitytoopioidreceptors.
Replacementofthe14-methoxygroupwithaphenylpropoxygroupledtoanenhancementinaffinityto
all three opioid receptor types, with most pronounced increases in δandκactivities, hence resulting in a
loss of μ receptor selectivity. All compounds (11-18) showed potent and long-lasting antinociceptive
effects in the tail-flick test in rats after subcutaneous administration. For the N-methyl derivatives 13
and14,analgesicpotencieswereintherangeoftheir14-methoxyanalogues9and10,respectively.Even
derivatives 15-18 with an N-cyclopropylmethyl substituent acted as potent antinociceptive agents,
being several fold more potent than morphine. Subcutaneous administration of compounds 13 and 14
produced significant and prolonged antinociceptive effects mediated through peripheral opioid
mechanisms in carrageenan-induced inflammatory hyperalgesia in rats.
Introduction
The clinical management of pain, especially severe and
chronic pain, is still a major challenge.
1,2 Analgesic drugs
suchasopioidsplaya centralrole in paincontrol.
2,3 Together
with endogenous opioids, they modulate nociceptive trans-
mission at different levels in the pain modulating pathways
via interaction with opioid receptors.
4-6 The efficacy of
currently used opioid analgesics, including morphine, oxy-
morphone, oxycodone, and fentanyl, is frequently asso-
ciated with the occurrence of undesired dose-limiting side
effects.
2,3 There is a continued search for opioids that are
highly efficacious withreduced complications andimproved
patient compliance.
Workinourlaboratoryhasbeenfocusedonthedevelopment
of new opioid agonists and antagonists from the morphinan
class of compounds.
7-9 Introduction of a 14-methoxy group
in oxymorphone resulted in 14-O-methyloxymorphone
10
(1; Figure 1), which not only increases affinity to opioid
receptors while retaining the μ receptor selectivity but also
markedly enhances the antinociceptive potency.
10-12 Further
work on 14-alkoxymorphinans led to the development of 14-
methoxymetopon
13(2;Figure1).Itwasreportedasaselective
and high efficacy μ opioid receptor agonist showing potent
centrally mediated antinociceptive effects and less pronounced
typicalopioidadverseactions.
12-18Aderivativeofthe14-alk-
oxymorphinan series of opioids, 14-phenylpropoxymetopon
19
(3; Figure 1), has been described as an extremely powerful
analgesic with high affinity for all three opioid receptor types
(μ, δ,a n dκ).
19Similarresults were provided ondifferently N-
substituted14-phenylpropoxymorphinan-6-ones(e.g.,N-allyl
and N-cyclopropylmethyl substituted morphinans 5 and 6).
20
It was established that the presence of a 14-phenylpropoxy
group increases both the agonist potency and the affinity
for all three opioid receptor types while concurrently dimin-
ishingtheselectivityforanyofthereceptors.Thetwoclassical
opioid antagonists naloxone (7)a n dn a l t r e x o n e( 8)w e r e
converted into highly active analgesic agents by introducing
a phenylpropoxy group in position 14 (compounds 5 and 6,
respectively).
20Moreover, derivatives of the selective μopioid
receptor antagonist cyprodime having a phenylpropoxy
group at C-14 have also acted as potent antinociceptives
in different pain models in mice after subcutaneous (sc)
administration.
21 Thus, the presence of this substituent
directs to a profound alteration in the pharmacological
profile of morphinan-6-ones.
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Traditionally, analgesic effects of opioids have been asso-
ciated with exclusive activation of opioid receptors in the
central nervous system (CNS
a). There is large evidence that
intrinsic pain control can also occur at peripheral sites,
6,22-24
which is supported by the identification of peripheral opioid
receptors on sensory neurons.
25,26 The contribution of the
opioid system to peripheral pain control mechanisms gained
considerable attention during the past years, leading to new
directions in research focusing on exploration of the thera-
peutic potential of peripheral opioid receptors for superior
management of pain.
6,23,24,27,28 Targeting peripheral mecha-
nismscanprovideselectiveperipheralanalgesiabyavoidingthe
central complications associated with the use of opioids.
6,23,27
Our research in the field of peripherally acting opioid
antinociceptiveagents hasledus toobtain a seriesof6-amino
acidsubstitutedderivatives(glycine,alanine,andphenylalanine)
of 14-O-methyloxymorphone (1).
29 These compounds dis-
played high affinities at the μ opioid receptor and showed
potent agonism.
30 A number of pharmacological studies
reported that amino acid substitution in position 6 of 14-O-
methyloxymorphone affords derivatives that produce potent
antinociceptiveactionsinrodentmodelsofacutenociception,
inflammatory, visceral, and neuropathic pain.
18,31-33 These
antinociceptiveeffectswereshowntobemediatedbyactivating
primarilyperipheralopioidreceptors.Theyshowedmarkedly
long-lasting antinociceptive actions compared to the conven-
tionalcentrallyactingμopioids,fentanyl,morphine,theparent
compound 1, and 14-methoxymetopon (2).
8,31-33 The most
potentcompoundswerethe6-glycine,14-methoxysubstituted
derivatives 9 and 10, respectively (Figure 1). The 6β-glycine
analogue10exhibitedanantinociceptivepotencycomparable
tofentanylandwasonly2-foldlowerthanthatof14-O-methyl-
oxymorphone (1) after sc administration.
31
In the present study, we have investigated the effect of a
combinationof6-aminoacidand14-phenylpropoxysubstitu-
tions in N-methyl- and N-cycloproplymethylmorphinans on
the biological profile represented by in vitro binding and
antinociceptive activities after sc administration to rats.
Structure-activity relationship (SAR) studies relating to
thesubstitutionpatterninpositions6and14withinthisseries
were pursued. To this aim, 6-glycine derivatives having a 14-
phenylpropoxy group (compounds 13, 14, 17,a n d18)w e r e
synthesizedandtheirinvitroandinvivoopioidactivitieswere
evaluated. We have also assessed the peripheral mechanisms
of antinociceptive effects of derivative 13 and 14 after sc
administration to rats with carrageenan-induced inflamma-
tory pain. In addition, the pharmacological properties of the
corresponding tert-butyl esters 11, 12, 15,a n d16 were in-
vestigated in order to extend the SAR in the series of 14-
alkoxymorphinans.
Chemistry. Reductive amination ofthe 14-phenylpropoxy-
morphinan-6-ones 4
21 and 6
20 was performed with glycine
tert-butyl ester hydrochloride and NaCNBH3 in DMF/
MeOH 10:1 at room temperature (Scheme 1). The diastereo-
isomers were separated by medium pressure liquid chroma-
tography (MPLC) toobtain 11, 12, 15,a n d16. Ester cleavage
of the tert-butyl derivatives in dioxane/HCl generated the
amino acids 13, 14, 17, and 18. Configuration assignments
at C(6) are based on the coupling constants (J(5,6)) between
H-C(5) and H-C(6). J(5,6) values for 6R-amino epimers
are smaller (3.2-4.0 Hz) than for 6β-amino epimers (6.5-
7.8 Hz).
29,34,35 The results for compounds 11-18 agree with
the earlier findings.
Results and Discussion
In Vitro Opioid Receptor Binding Affinities. Binding affi-
nities of the newly synthesized compounds 11-18 at opioid
receptors were determined by in vitro competition binding
assays using rat brain (μ, δ) and guinea pig brain (κ) mem-
branesandemploying[
3H][D-Ala
2,Me-Phe
4,Gly-ol
5]enkephalin
([
3H]DAMGO, μ),
36 [
3H][Ile
5,6]deltorphin II (δ),
37 and [
3H]-
(5R,7R,8β-(-)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro(4-
5)dec-8-yl]benzeneacetamide) ([
3H]U69,593, κ)
38 as specific
opioid radioligands.
30 The μ, δ, and κ opioid receptor
binding affinities expressed as inhibition constants (Ki) are
summarized in Table 1. The selectivity for the μ opioid
receptor vs δ and κ receptors was defined by the ratio of
Figure 1. Structures of ligands related to 14-O-methyloxymor-
phone (1), naloxone (7), and naltrexone (8). CPM, cycloproply-
methyl; Ph, phenyl.
Scheme 1. Synthesis of 14-Phenylpropxymorphinans 11-18
a
aReagents and conditions: (a) glycine-t-butylester hydrochloride,
NaCNBH3, DMF/MeOH 10:1, RT; (b) separation of the diastereo-
isomers using column chromatography (silica gel); (c) 4 M HCl in
dioxane, reflux.
aAbbreviations:CHO,Chinesehamsterovary;CNS,centralnervous
system; DAMGO, [D-Ala
2,Me-Phe
4,Gly-ol
5]enkephalin; DMF, N,N-
dimethylformamide; DPDPE, [D-Pen
2,D-Pen
5]enkephalin; HEPES,
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; GDP, guanosine
diphosphate; [
35S]GTPγS, guanosine-50-O-(3-[
35S]thio)-triphosphate;
MPLC, medium pressure liquid chromatography; SAR, structure-
activity relationship; Tris, tris-(hydroxymethyl)-aminomethane; U69,593,
5R,7R,8β-(-)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro(4-5)dec-8-yl]-
benzeneacetamide.982 Journal of Medicinal Chemistry, 2011, Vol. 54, No. 4 Spetea et al.
the Ki values. For comparison purposes, the opioid binding
affinity data for morphine, 3, the 6R- and 6β-glycine con-
jugates of 14-O-methyloxymorphone, 9 and 10, respectively,
and the 14-phenylpropoxy analogue of naltrexone, com-
pound 6, are included. All compounds 11-18 bound with
high affinity at the μ opioid receptor (Ki=0.16-1.40 nM),
having considerably improved interaction with the μ site
compared to morphine. As shown in Table 1, they also exhibit
increased binding affinities at δ and κ receptors as indicated
by the Ki values in the subnanomolar or low nanomolar
range.
To investigate the SAR for the novel 14-alkoxymorphi-
nans, the following structural modifications were targeted:
(i) replacement of the methoxy group with a phenylpropoxy
groupinposition14,(ii)substitutionoftheN-methylwithan
N-cyclopropylmethyl group, (iii) modification of the sub-
stituent at position 6 (e.g., 6-glycine vs 6-glycine ester vs
6-keto), and (iv) R vs β orientation of the amino acid residue
at C-6 of the morphinan skeleton. First, we have examined
the result of the replacement of the 14-methoxy group in N-
methyl substituted morphinans 9 and 10 with a phenylpro-
poxy group, leading to compounds 13 and 14, respectively,
ontheinvitroopioidbindingprofile.Whiletheμaffinitywas
less affected, affinities at δ and κ receptors were increased
significantly after introduction of a phenylpropoxy substi-
tuent (Table 1). Compared to analogues 9 and 10, affinities
of the 14-phenylpropoxy substituted derivatives 13 and 14
wereincreasedbyabout 7-and5-foldatμ,70-and42-foldat
δ, and 59- and 55-fold at κ receptors, respectively. On the
basis ofthese data, it appears thata phenylpropoxygroup in
position 14 is not favorable for selective binding to μ, δ,o rκ
receptors by causing a notable loss in μ receptor selectivity,
thus, corroborating and extending our previous findings in
other series of 14-phenylpropoxy substituted morphinans.
19,20
Thepresentobservationstogetherwithearlierreports
10,11,19,20,39,40
provide additional evidence that interaction with opioid
receptors is sensitive to the character and length of the
substituent in position 14. It has been shown that different
substitution patterns at C-14 in morphinan-6-ones give rise
to compounds with improved or decreased selectivity for the μ
receptor. An enhancement in the binding affinity at δ and κ
receptors has been reported with other substituents at position
14suchasbenzyloxyornaphthylmethoxy.
11Wehavedescribed
that a 14-methoxy group results in higher selectivity for
the μ receptor than 14-benzyloxy or 14-naphthylmethoxy
substitution, indicating that small alkoxy groups are supe-
rior over arylalkoxy groups in this respect.
11 In contrast,
replacement of the 14-methoxy with a phenylpropoxy group
in cyprodime and other 4,5-oxygen bridge opened morphi-
nan-6-oneswasfoundtomarkedlyincreasebindingaffinities
at μ but also at δ and κ receptors, however retaining μ
selectivity.
21
The effect on the opioid receptor binding profile upon
different substitution at the nitrogen of the morphinan
skeletonwasalsoinvestigated.ReplacementoftheN-methyl
group in 13 and 14 by a cyclopropylmethyl group resulted in
analogues 17 and 18, respectively. The N-cyclopropylmethyl
substitution was well-tolerated as indicated by the high
affinityforallμ,δ,andκreceptors(Kivaluesinthesubnano-
molar range; Table 1). Further evidence for this observation
comesfromourpreviousworkswherenearlyidenticalaffinities
for all opioid receptor types were noted for 3
19 and naltrex-
one derivative 6.
20 It appears that modification of the N-
substituent, methyl vs cyclopropylmethyl, causes no major
alterations in binding affinity and selectivity in this series of
opioid compounds. In other series of morphinans which are
unsubstituted or have a hydroxyl or a small alkoxy group at
C-14, substitution of the N-methyl by a N-cyclopropyl-
methylgroupleadstoanincreaseinaffinityatδandκopioid
receptors but also to a raise in μ affinity, resulting in reduced
μ receptor selectivity.
11,41,42 A representative example is the
comparison of binding affinities of oxymorphone (μ:δ:κ =
0.97:80.5:61.6)
11withitsN-cyclopropylmethylanaloguenal-
trexone (μ:δ:κ = 0.20:8.70:0.40).
42 On the other hand, it has
been shown that replacement of the N-methyl group in 14-
methoxymetopon (2) with a 2-phenylethyl group left the
binding affinities at μ and δ opioid receptors essentially
unchanged but affected interaction with the κ receptor.
11
In view of these results, the nature of the substituent at the
nitrogen has a significant effect on both opioid receptor
binding affinity and selectivity of the morphinan class of
opioidcompounds,dependingonthecharacterandlengthof
the substituent in position 14.
The effect on opioid receptor binding affinities upon
substitutionofaketogroupwithaglycineresidueinposition
6 in the N-methyl and N-cyclopropylmethyl 14-phenylpro-
poxy substituted morphinans was examined. The 6-glycine
conjugates 13 and 14 displayed similar binding affinities to
all three opioid receptors as the 6-keto derivative 3.M o r e o v e r ,
in the N-cyclopropylmethyl series, in a direct comparison of
Table 1. Binding Affinities at μ, δ and κ Opioid Receptors
Ki (nM)
a selectivity ratio
compd μ receptor [
3H]DAMGO
b δ receptor [
3H][Ile
5,6]deltorphin II
b κ receptor [
3H]U69,593
c δ/μ κ/μ
morphine
d 6.55(0.74 217(19 113(9
a 33 17
3
e 0.20(0.05 0.14( 0.02 0.54(0.15 0.7 2.7
6
f 0.34(0.06 0.48(0.05 0.41(0.09 1.4 1.2
9
g 0.89(0.09 15.4(1.4 43.2 (7.0
a 17 49
10
g 0.83(0.02 7.86(0.64 44.8(0.1
a 10 54
11 1.40 (0.07 1.01(0.06 1.26( 0.30 0.7 0.9
12 1.03(0.25 0.92 (0.16 2.02(0.68 0.9 2.0
13 0.19(0.02 0.22(0.02 0.73 (0.01 1.2 3.8
14 0.16(0.02 0.19(0.01 0.81(0.03 1.2 5.1
15 1.38(0.21 1.11(0.07 1.49 (0.27 0.8 1.1
16 1.01(0.21 0.40(0.07 1.77(0.37 0.4 1.8
17 0.27(0.02 0.33(0.10 0.64 (0.01 1.2 2.4
18 0.20(0.04 0.35(0.04 0.65(0.01 1.7 3.2
aValues represent the mean ( SEM.
bRat brain membranes were used.
cGuinea pig brain membranes were used.
dFrom ref 17.
eFrom ref 19.
fFrom
ref 20.
gFrom ref 30.Article Journal of Medicinal Chemistry, 2011, Vol. 54, No. 4 983
the 14-phenylpropoxy analogue of naltrexone (6) with the
6-glycine derivatives 17 and 18, all compounds showed
comparable affinities at μ, δ, and κ receptors (Table 1).
According to the present results, the 6-glycine derivatives
having a 14-phenylpropoxy group maintained the high affinity
at the μ opioid receptor of the nonzwitterionic compounds 3
and 6, which is in agreement with a further SAR report in
other series of 14-methoxymorphinans containing zwitterionic
moieties such as amino acid residues.
29,30 Thus, it is evident
that replacement of the 6-keto group with a glycine residue
does not have a detrimental effect on affinity at the μ
receptor. Analogous observations were made for β-oxymor-
phamine
43 and β-naltrexamine
44 when having ionizable
moietiesatC-6.Also,ithasbeenshownin4,5-oxygenbridge
opened N-methylmorphinans that a 6-cyano substituent in
comparison to a 6-keto group has a minor impact on the
abilitytointeractwithopioidreceptors.
45Thesefindingsindicate
that replacement of the 6-keto group with other substituents
such as amino acids or a cyano group produces only minor
changes in the opioid binding profile of morphinans.
The consequence of esterification of the glycine residue at
C-6 on binding affinity and selectivity was also investigated.
As shown in Table 1, the tert-butyl ester derivatives 11, 12,
15, and 16 exhibited a decrease in the affinity at μ, δ, and κ
opioidreceptors comparedtothe6-glycine analogues13,14,
17, and 18, respectively. An exception was ester 16, which
showed comparable δ receptor affinity to analogue 18 (0.40
vs 0.35 nM). However, all esters still display high interaction
with opioid receptors as indicated by the Ki values in the low
nanomolar range (1.01-1.40 nM at μ, 0.40-1.11 nM at δ,
and 1.26-2.02 nM at κ receptors). On the other hand, the
esters also showed to lack selectivity to a receptor type
similar to the corresponding 6-glycine analogues.
When examining the impact of R/β orientation of the
amino acid residue at position 6 on thein vitro opioid activity,
it was noted that binding affinities and selectivities of R vs β
epimers did not vary greatly in this series of newly synthe-
sized 14-phenylpropoxymorphinans (Table 1).
Pharmacological Activities. The 6-glycine substituted 14-
phenylpropoxymorphinans 11-18 were further evaluated in
vivoforantinociceptiveeffectsinratsafterscadministration
using the tail-flick test.
31 Their antinociceptive properties
were compared to those of morphine and derivatives 9 and
10. The antinociceptive ED50 values are listed in Table 2. All
compoundsactedaspotentantinociceptiveagentswithlong-
lasting action when administered sc, with peak ED50so f
26.8-349 nmol/kg. Peak antinociception occurred generally
one hour after drug sc administration, and only derivatives
14 and 18 had a peak of action at two hours postinjection.
Compared to morphine, the 14-phenylpropoxymorphinans
of this series showed 17- to 226-fold increased analgesic
potency, with compound 16 displaying the highest potency
(Table 2). Antinociceptive potencies of the 6-glycine sub-
stituted 14-phenylpropoxy derivatives 13 and 14 were in the
range of their 14-methoxy analogues 9 and 10, respectively
(Table 2). It appears that a 14-phenylpropoxy substitution
maintains the high analgesic activity, while it largely affects
opioid binding affinities and μ receptor selectivity (Table 1).
Traditional and generally accepted SAR models have
assigned critical importance in defining the pharmacological
profile of agonist/antagonist action of morphinan-6-ones to
the substitutent at the morphinan nitrogen.
46-48 Substitu-
ents such as cyclopropylmethyl or allyl at the nitrogen have
been commonly associated with an antagonist character in
this series of opioids. On the other hand, there are a number
of examples where substitution at C-14 affords potent analge-
sics independent of the substituent nature at the morphinan
nitrogen.
11,19-21,39,40EvenwithaN-substituentthatislinked
with distinct antagonist character such as cyclopropyl-
methyl,antinociceptiveagentscanbeobtainedandexamples
Table 2. Antinociceptive Potencies in the Tail-Flick Test in the Rat after sc Administration
ED50 (nmol/kg, sc), 95% CL
a
time after drug administration
compd 0.5 h 1 h 2 h 3 h
relative potency
b
morphine = 1
morphine 6053
c 7626 13285 1
(4037-9080) (5084-11439) (8856-19929)
9
d 137 58.5
c 143 437 103
(85.7-219) (36.5-93.7) (86.8-237) (243-786)
10
d 50.8 29.0
c 43.3 209
(32.7-78.7) (18.8-44.9) (27.9-67.1)
11 63.5 58.3
c 84.0 148 104
(15.4-262) (18.0-188) (31.4-255) (28.4-775)
12 164 92.3
c 124 189 66
(78.6-341) (39.5-215) (53.0-292) (69.8-514)
13 127 81.1
c 87.9 116 75
(65.0-246) (46.4-139) (43.9-176) (48.5-278)
14 180 143 130
c 192 47
(122-247) (85.8-238) (73.4-231) (90.0-414)
15 365 348
c 363 427 17
(195-687) (212-570) (215-615) (205-692)
16 33.8 26.8
c 34.4 56.0 226
(18.8-60.5) (14.1-51.0) (17.7-66.8) (21.9-143)
17 1388 349
c 433 543 17
(117-16526) (113-1072) (172-1084) (180-1636)
18 1561 183 147
c -
e 41
(199-12223) (17.7-1877) (13.9-1554)
aValues in paranthesis are 95% confidence limits.
bRelative potencies were calculated at the peak of action.
cPeak of effect.
dFrom ref 31.
e-: no dose-response relationship.984 Journal of Medicinal Chemistry, 2011, Vol. 54, No. 4 Spetea et al.
include the clinically used buprenorphine,
49 nalfurafine
(TRK-820)anditsanalogues,
50,51and14-aminomorphinone
derivatives.
39,40 In the present study, the N-cyclopropyl-
methyl substituted compounds 17 and 18 and their corre-
sponding tert-butyl esters 15 and 16 showed potent
antinociceptive activities in rats after sc administration
(Table 2). The in vivo pharmacology of derivatives 17 and
18 as antinociceptive agents was also supported by the
functional data on the ligand-stimulated guanosine-50-
O-(3-[
35S]thio)-triphosphate ([
35S]GTPγS) binding to mem-
branes from Chinese hamster ovary (CHO) stably transfected
with human opioid receptors
21 (Table 3). Both compounds
were highly potent partial agonists at the μ receptor and also
at δ and κ receptors so that no significant selectivity for any
receptor type was apparent. It is suggested that such com-
poundswhichinteractwithmultiplereceptortypesmayhave
an overall increased potency derived from the combined action
at μ, δ, and κ opioid receptors.
52 Moreover, as found in this
and our earlier studies
11,19-21 and also by others,
39,40,53-55
notnecessarilythenatureofthesubstituentatthenitrogenin
morphine-like compounds but rather residues occupying a
defined position in the vicinity to the morphinan nitrogen
seem to be responsible for agonist/antagonist activity. Our
SAR study also showed that replacement of the N-methyl
group of compounds 13 and 14 with a cyclopropylmethyl
group resulted in analogues 17 and 18, respectively, which
retained the high antinociceptive potency after sc adminis-
tration (Table 2). This holds also true when evaluating the
N-methyl substituted 3
19 and naltrexone derivative 6,
20
which show comparable antinociceptive potencies in differ-
ent analgesic tests in mice after sc administration.
AsshowninTable2,esterificationoftheglycineresiduein
position 6 did not result in major alterations in antinocicep-
tiveactivitiesandalltert-butylesterswerefoundtobegreatly
active displaying similar potencies to their corresponding
glycine analogues. Notably, the N-cyclopropylmethyl tert-
butyl ester 16 was about 6-fold more potent than derivative
18. In the tail-flick test, antinociceptive potencies did not
significantly differ between the R and β epimers, which is in
agreement with the in vitro biological data where also no
major changes in opioid binding affinities were observed.
Their ED50 ratios were ranging between 0.6 and 2.4 after sc
administration, except for the pair 15 vs 16, where a 13-fold
difference in the potency was calculated.
Opioids with hydrophilic groups such as amino acid
residuesattachedtotheC-6positionofthemorphinanskeleton
were targeted in an effort to obtain opioid compounds that
wouldhavepotentiallylimitedaccesstotheCNSandthusto
Table 3. Stimulation of [
35S]GTPγS Binding
a
μ receptor δ receptor κ receptor
compd EC50 (nM) % stim
b EC50 (nM) % stim
c EC50 (nM) % stim
d
17 0.69(0.10 34.7(6.6 0.69(0.29 26.1(3.0 1.28 (0.35 28.2(1.0
18 1.06(0.28 24.2 (3.0 4.24(0.47 34.7( 0.6 11.0(1.4 30.4(3.3
morphine 15.6(0.5 93(2.8 316(5 103( 7 484(213 62(7
aMembranesfromCHOcellsstablytransfectedwithhumanμ,δ,orκopioidreceptorswereincubatedwithvaryingconcentrationsofthecompounds.
bCompared to DAMGO.
cCompared to DPDPE.
dCompared to U69,593. Data represent mean ( SEM.
Figure 2. (A) Antinociceptive effects of 6-glycine substituted 14-phenylpropoxymorphinans 13 and 14 after sc administration to rats with
carrageenan-inducedinflammatoryhyperalgesia.(B)Antagonismbynaloxonemethiodide(NM)ontheantinociceptiveeffectofcompound13
and 14 after sc coadministration on the inflamed paw withdrawal latencies to mechanical stimulation. Values are presented as % changes in
withdrawallatenciesoftheinflamedpawfromthepretreatment(pre-)valuesobtainedat3haftercarrageenaninjection.Areasunderthecurves
(AUC) ofthe respective time curves are represented. Data are shown as mean( SEM *p<0.05, **p<0.01, and ***p<0.001 vs vehicle-treated
controls;
#p<0.05 vs agonist-treated animals.Article Journal of Medicinal Chemistry, 2011, Vol. 54, No. 4 985
reduce the activation of central opioid receptors. We have
reportedonthepotentantinociceptiveactionofthe6-glycine
conjugateof14-O-methyloxymorphone,compound10,after
systemic sc administration to rats with carrageenan-induced
inflammatory hyperalgesia.
18 Further in vivo pharmacolo-
gical studies were undertaken in the present study with the
14-phenylpropoxy derivative of 10, compound 14, and its
corresponding 6R-glycine analogue 13 to assess their anti-
nociceptive actions in a rat model of inflammatory pain.
Subcutaneous administration of compounds 13 and 14,i na
dose of 170 nmol/kg, produced a significant attenuation in
pain-related behavior in the inflamed paw by increasing
withdrawal latencies to mechanical stimulation having a
long duration of action (up to 4 h) (Figure 2A). These
observations are in line with the earlier pharmacological
findingsonpotentandprolongedinhibitoryeffectsofthe14-
methoxy 6-glycine analogue 10 in rats with inflammatory
hyperalgesia.
18Moreover, itsantinociceptiveactionsaftersc
administration was shown to be mediated through periph-
eral mechanisms not only in carrageenan-induced hindpaw
inflammation
18 but also in other rodent pain models in-
cluding tail-flick test,
31 formalin test,
31 and acetic acid-
induced writhing.
32 The antinociceptive efficacy of deriva-
tives 13 and 14 in tested sc doses in carrageenan-induced
inflammatory pain was comparable to that reported for
compound10afterascdoseof100μg/kg(i.e.,183nmol/kg)
andwithmarkedlylongerdurationofactionthanmorphine
and 14-methoxymetopon (2).
18 To evaluate whether the
antinociceptive effect of the 14-phenylpropoxy substituted
derivatives 13 and 14 in rats with carrageenan-induced
hyperalgesia is peripherally mediated, naloxone methio-
dide, the peripherally acting opioid antagonist, was sc
coadministered with each opioid. As shown in Figure 2B,
naloxone methiodide (426 nmol/kg) significantly reversed
the antinociceptive effect of a 170 nmol/kg dose of com-
pound 13 and 14 on mechanical hyperalgesia. Hence,
replacement ofthe 14-methoxygroupincompound10 with
a phenylpropoxy group gave rise to new derivatives show-
ing peripherally mediated antinociceptive action in a rat
model of inflammatory pain. Outcomes of these studies
extend our earlier reports on 6-amino acid substituted
derivatives (i.e., glycine, alanine and phenylalanine) of 14-
O-methyloxymorphone (1)
18,29-33 described as high affi-
nity μ opioid receptor agonists that can induce potent
antinociceptive effects via peripheral opioid receptor-
specific mechanisms.
Conclusions
We have described the synthesis and biological activities of
a series of new 6-glycine substituted 14-phenylpropoxymor-
phinans which emerged as high affinity and potent opioid
antinociceptive agents. Specific modifications in the substitu-
tion pattern, such as introduction of a 14-phenylpropoxy
group and a glycine residue atposition 6, led toaninteresting
alteration in opioid activity by influencing the biological
profileofthesecompoundsinteractingwithμ,δ,an dκopioid
receptors. On the basis of the SAR that has emerged, it could
be observed that there is a significant enhancement in affinity
at all opioid receptor types upon introduction of a phenyl-
propoxy group at position 14 in 6-glycine substituted mor-
phinans,withmostpronouncedincreasesinactivityatδandκ
receptors, leading to a loss in μ receptor selectivity. In vitro
binding affinities to all opioid receptors and selectivity were
not appreciably affected upon substitution of the N-methyl
withacyclopropylmethylgroup.Besidestheincreasedaffinity
for opioid receptors, another attribute of the new 6-glycine
substituted 14-phenylpropoxymorphinans is the potent and
long-lastingantinociceptive effectsin rats after sc administra-
tion, displaying considerably increased potency than mor-
phine.FortheN-methylderivatives13and14,antinociceptive
potencies were in the range of their 14-methoxy analogues.
Even derivatives 15-18 having a N-cyclopropylmethyl sub-
stituent acted as highly active antinociceptive agents, being
several fold more potent than morphine. Subcutaneous ad-
ministration of the N-methyl 6R-a n d6 β-glycine substituted
14-phenylpropoxymorphinans 13 and 14, respectively, signif-
icantly reduced mechanical hypersensitivity in rats with car-
rageenan-induced inflammatory pain, effects shown to be
mediated via activation of peripheral opioid receptors. Such
peripherally acting opioids may represent novel drug candi-
dates for pain treatment.
Experimental Section
General Methods. The starting material thebaine was obtained
from Tasmanian Alkaloids Ltd., Westbury, Tasmania, Australia.
Melting points were determined on a Kofler melting point micro-
scope and are uncorrected.
1H NMR spectra were obtained on a
Varian Gemini 200 (200 MHz) spectrometer using tetramethyl-
silane(TMS)asinternalstandardforCDCl3and3-(trimethylsilyl)-
1-propanesulfonic acid sodium salt (DSS) for D2O. Coupling
constants (J) are given in Hz. IR spectra were taken on a Mattson
Galaxy FTIR series 3000 in KBr pellets (in cm
-1). Mass spectra
were recorded on a Varian MAT 44 S apparatus. Elemental
analysis was performed at the Institute of Physical Chemistry of
the University of Vienna, Austria. For column chromatography
(MPLC),SilicaGel60(0.040-0.063mm,Fluka,Switzerland) was
used. Thin-layer chromatography (TLC) was performed on silica
gel plates Polygram SIL G/UV254 (Macherey-Nagel, Germany)
with CH2Cl2/MeOH/NH4OH 90:9:1 as an eluent.
Radioligands [
3H]DAMGO, [
3H]U69,593, and [
35S]GTPγS
were purchased from PerkinElmer (Boston, MA, USA).
[
3H][Ile
5,6]deltorphin II was obtained from the Institute of
Isotopes Co. Ltd. (Budapest, Hungary). Naloxone hydrochloride,
tris-(hydroxymethyl)-aminomethane(Tris),carrageenan(λ-car-
rageenan), naloxone methiodide, GTPγS, guanosine diphosphate
(GDP), and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES) were obtained from Sigma Chemicals (St. Louis, MO,
USA).Allotherchemicalswereofanalyticalgradeandobtained
from standard commercial sources. Compounds 11, 12, 15, and
16 were used as bases and compounds 13, 14, 17, and 18 were
used as hydrochloride salts. Purities of tested compounds were
determined by elemental analysis and were g95%.
General Procedure for the synthesis of 13, 14, 17, and 18 (13 as
example).1 1(0.18 g; 0.35 mmol) was dissolved in 5 mL of 4 M
HCl in dioxane and stirred under reflux for 2 h. The colorless
crystalswerefilteredoffundernitrogen,washedwithanhydrous
diethyl ether, and dried.
[[4,5r-Epoxy-3-hydroxy-17-methyl-14β-[(3-phenylpropyl)oxy]-
morphinan-6r-yl]amino]acetic Acid Dihydrochloride (1332HCl).
Colorless crystals (89%); mp>207  C (dec). IR (KBr) 1744
(CdO).
1HNMR (D2O)δ 7.47-7.35(m, 5aromH), 6.96(d,J=
8.3, 1 arom H), 6.87 (d, J=8.3, 1 arom H), 5.09 (d, J=3.2,
H-C(5)), 3.01 (s, CH3N). MS (ESI) m/z 479 [Mþ1]
þ. Anal.
(C28H34N2O532HCl31.9H2O) C, H, N.
[[4,5r-Epoxy-3-hydroxy-17-methyl-14β-[(3-phenylpropyl)oxy]-
morphinan-6β-yl]amino]acetic Acid Dihydrochloride (1432HCl).
Colorless crystals (93%). mp>217  C (dec). IR (KBr) 1740
(CdO).
1HNMR(D2O)δ7.44(s,5aromH),6.94(s,2aromH),
4.96(d,J=7.0,H-C(5)),2.99(s,CH3N).MS(ESI)m/z479[Mþ
1]
þ. Anal. (C28H34N2O532HCl32H2O) C, H, N.986 Journal of Medicinal Chemistry, 2011, Vol. 54, No. 4 Spetea et al.
[[17-Cyclopropylmethyl-4,5r-epoxy-3-hydroxy-14β-[(3-phenyl-
propyl)oxy]morphinan-6r-yl]amino]acetic Acid Dihydrochloride
(1732HCl). Colorless crystals (97%); mp>218  C (dec). IR
(KBr) 1741 (CdO).
1H NMR (D2O) δ 7.29 (s, 5 arom H), 6.85
(d,J=8.2,1aromH),6.75(d,J=8.2,1aromH),4.99(d,J=3.0,
H-C(5)), 0.93 (m, CH-cp), 0.66 (m, CH2-cp), 0.36 (m, CH2-cp)
(cp=cyclopropyl). MS (CI) m/z 519 [M þ 1]
þ. Anal. (C31H38-
N2O532HCl31.4H2O) C, H, N.
[[17-Cyclopropylmethyl-4,5r-epoxy-3-hydroxy-14β-[(3-phenyl-
propyl)oxy]morphinan-6β-yl]amino]acetic Acid Dihydrochloride
(1832HCl).Colorlesscrystals(89%);mp>223 C(dec).IR(KBr)
1741 (CdO).
1H NMR (D2O) δ 7.42 (s, 5 arom H), 6.94 (s, 2
arom H), 4.99 (d, J=7.0 H-C(5)), 1.02 (m, CH-cp), 0.82-0.68
(m, CH2-cp), 0.46 (m, CH2-cp) (cp=cyclopropyl.MS (CI) m/z
519 [M þ 1]
þ. Anal. (C31H38N2O532HCl31.7H2O) C, H, N.
Opioid Receptor Binding Assays. Membranes were prepared
from Sprague-Dawley rat or guinea pig brains, obtained from
theInstitutf€ urLabortierkundeandLaborgenetik,Medizinische
Universit€ atWien(Himberg,Austria),aspreviouslydescribed.
30
Binding experiments were performed in 50 mM Tris-HCl buffer
(pH 7.4.) in a final volume of 1 mL containing 0.3-0.5 mg of
protein and at least 10 concentrations of test compound as
described.
18 Rat brain homogenates were incubated either with
[
3H]DAMGO (1 nM, 45 min, 35  C) or [
3H][Ile
5,6]deltorphin II
(0.5 nM, 45 min, 35  C). Guinea pig brain homogenates were
incubated with [
3H]U69,593 (1 nM, 30 min, 30  C). Reactions
were terminated by rapid filtration through Whatman glass
fiber filters using a Brandel M24R cell harvester, followed by
washing with 50 mM Tris-HCl buffer (pH 7.4). Nonspecific
binding was determined using 10 μM naloxone. The bound
radioactivity was measured by liquid scintillation counting.
Inhibition constant (Ki) values were calculated from competition
binding curves using the nonlinear least-squares curve fitting by
GraphPad Prism program. All experiments were performed in
duplicate and repeated at least three times.
[
35S]GTPγS Functional Assays. Functional assays were con-
ducted on human opioid receptors stably transfected into CHO
cellsasdescribed.
21Aliquotsofcellmembranes(15μg)inbuffer
A (20 mM HEPES, 10 mM MgCl2 and 100 mM NaCl, pH 7.4)
wereincubatedwith0.05nM[
35S]GTPγS,10μMGDP,andtest
compounds, in a total volume of 1 mL, for 60 min at 25  C.
Nonspecific binding was determined using 10 μMG T P γS.
Samples are filtered over glass fiber filters and counted as
described for binding assays. Potency (EC50, nM) and percentage
of stimulation (% stim) with respect to the standard agonists
DAMGO (μ), DPDPE (δ), and U69,593 (κ) were calculated
using GraphPad Prism program. The results are mean (
SEM from at least three determinations, each performed in
triplicates.
InVivoAssays.GeneralMethods.MaleWistarrats(120-150g)
used in the tail-flick test were purchased from Charles River
(Budapest, Hungary). Male Sprague-Dawley rats (250 g) used
in carrageenan-induced inflammatory pain were purchased
form B&K Universal Lab (Sollentuna, Sweden). Animals were
maintained on a 12 h light/dark cycle with free access to food
and water at all times except during testing. Experiments were
carried out in accordance tothe Declaration of Helsinki and the
Guide for Care and Use of Laboratory Animals. The experi-
mental protocols were approved by the Ethical Board of Sem-
melweis University, Budapest, and Ethics Committee for Animal
Research (North Stockholm, Sweden).
Tail-FlickTest.Thetail-flicktestwasperformedaccordingto
the described procedure.
31 A beam light was focused on the tip
of the tail and the latency required for the rat to remove its tail
was determined before (basal latencies) and after drug admin-
istration, using an arbitrary cutoff time of twice the basal reaction
time. Compounds weredissolved indistilled water andadminis-
tered sc to rats in a volume of 5 mL/kg of body weight. Each
drug dose or vehicle (distilled water) was tested in at least five
animals.Theeffectivedose50%(ED 50)valuesand95%confidence
limits werecalculated according tothe methodof Litchfieldand
Wilcoxon.
56
Carrageenan-Induced Hindpaw Inflammation. Unilateral in-
flammation was induced to nonanesthetized rats by injection of
100 μL of 1% carrageenan into the plantar surface of the right
hindpaw as previously described.
18 All treatments were per-
formed 3 h after carrageenan injection. Compounds were dis-
solved in physiological saline (0.9%) and administered sc in a
volume of 100 μL. Control animals received the same volume of
sc physiological saline solution. Each experimental group included
four to seven animals. The Randall-Selitto test (Ugo Basile)
wasusedtoassessthehindpawwithdrawallatenciestomechanical
stimulation as described.
18 A wedge-shaped, blunt piston with
anareaof1 10mm
2andaloadingrateof48g/swasappliedto
the dorsal surface of the manually handled hindpaw, and the
time required to initiate the struggle response was assessed and
expressed in seconds. A cutoff time of 20 s was applied. With-
drawal latencies to mechanical stimulation were measured
before injection of carrageenan (basal values), prior to admin-
istration of the drug 3 h postcarrageenan (pretreatment values),
and after drug administration. The antinociceptive response is
expressed as percentage (%) changes in hindpaw withdrawal
latencies from the pretreatment value obtained at 3 h after
carrageenan injection, and was calculated as 100 [(PX - P0)/
P0], where P0 is the latency prior to drug administration at 3 h
postcarrageenanandPXisthelatencyafterdrugadministration
at corresponding time points.
Statistical Analysis. Data are expressed as mean ( SEM. The
areasunderthecurves(AUC)werecalculatedbythetrapezoidal
ruleusingNCSSsoftware.Statisticalanalysiswascarriedoutusing
one-way analysis of variances (ANOVA) with Dunnett’s post
hoc test using SPSS software. A p value <0.05 was considered
statistically significant.
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